compounding semaglutide fda news FDA moves to stop compounding GLP-1 drugs Compounded versions of weight loss – US FDA proposes curbs on

Water, Centella Asiatica Leaf Water, Butylene Glycol, Glycerin, Dipropylene Glycol, Niacinamide, Hydroxyethyl Urea, Sodium Hyaluronate, Allantoin, Panthenol, Glutathione, Nelumbo Nucifera Extract, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Saccharomyces Ferment, Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract, Hydrolyzed Collagen, Beta-Glucan, Hippophae Rhamnoides Fruit Extract, Adenosine, Madecassic Acid, Asiaticoside, Asiatic Acid, Squalane, Caprylic/Capric Triglyceride, Hydrogenated Lecithin, Glyceryl Stearate, Xanthan Gum, Propanediol, Hydroxyacetophenone, 1,2-Hexanediol, Ethylhexylglycerin, Dipotassium Glycyrrhizate, Citric Acid, Sodium Citrate

It is not a GLP-1 receptor agonist

The Deprescribing Model Unlike practitioners who prescribe GLP-1s for indefinite use, providers like Eliszewski and Class set out with deprescribing in mind

It works well with topical treatments